Thus, the tight regulation of p53 levels and its activity along distinct developmental stages is required for proper development. Whether p53 exerts its role in developmental regulation through its abilities to induce cell-cycle arrest and apoptosis, or whether other activities are at play is still uncertain. Nevertheless, its participation in embryonic development may also point at its involvement in differentiation programs that occur in adult tissues. In the following sections we will elaborate on key studies that implicated p53 along regulatory networks of various differentiation programs.
p53 and neural differentiation
During neural development, neuronal death is a fundamental process whereby approximately half of the neurons produced in the nervous system die to ensure the establishment of appropriate neural connections [28] . The most prominent effect of p53 deficiency is evident as deranged neuronal development resulting in exencephaly in approximately a quarter of p53-KO embryos. This neural tube malformation is a result of either extensive cell outgrowth or reduced apoptosis in the neural tissue [12, 13] . The partial penetrance of the exencephalic phenotype suggests the existence of a compensatory mechanism, probably mediated by the other p53 family members, p63 or p73 [28] . At the cellular level, p53 was shown to be involved in the regulation of proliferation and differentiation of neural progenitor cells, promotion of neuronal maturation and axonal growth and regeneration following neuronal injury [29] .
The induction of neuronal differentiation involves two interrelated cellular processes; progression through the stages of neurite outgrowth and cell-cycle arrest [30] . Neuronal precursors derived from p53-KO mice display an enhanced proliferative potential, supporting a specific role for p53 in mediating an antiproliferative signal to neurons [31] . Using primary cultures of rat oligodendrocytes and neurons, as well as of the neuronal pheochromocytoma cell line, PC12, it was demonstrated that during differentiation, p53 translocates into the nucleus, whereas in mature differentiated cells it is present mainly in the cytoplasm.
Inhibition of p53 activity by introduction of a dominant-negative p53 protein inhibited the differentiation of oligodendrocytes and of PC12 cells and protected neurons from spontaneous apoptotic death. These findings suggest that p53 plays a regulatory role in directing primary neurons and oligodendrocytes toward differentiation or apoptosis in vitro [32] . In PC12 cells, p53-dependent activation of nerve growth factor (NGF) receptor is required for the transduction of the NGF signalling, which leads to growth arrest and differentiation [33] [34] [35] . By utilizing a genome-wide chromatin immunoprecipitation cloning technique of NGF treated PC12 cells, Brynzka and colleagues unraveled novel p53-regulated genes. The most prominent differentiation-relevant target genes included Wnt7b, which is involved in dendritic extension, and Grhl3, which is implicated in ectodermal development.
These authors concluded that p53 transcriptional activity is involved in PC12 differentiation and suggested a direct contributory role for p53 in neuronal development [36] . 
Involvement of p53 in osteogenic differentiation
The differentiation of osteoblasts from mesenchymal precursors requires a series of cell fate decisions controlled by a hierarchy of transcription factors. In particular, RunX2 and Osterix are key differentiation regulators which function together to commit progenitor cells towards the osteoblast lineage [39, 40] . The involvement of p53 in osteogenic differentiation and bone formation is intriguing since it plays opposite molecular roles during normal development compared with tumorigenesis. i.e., whereas p53 attenuates the course of bone formation and differentiation of early osteogenic precursors; it promotes terminal differentiation of tumor-forming osteogenic cells and by this attenuates the cancerous outcome [41] .
Induction of differentiation is usually considered as one of p53 tumor-suppressive activities. Therefore, it was surprising to reveal that p53 functions as a negative regulator of osteoblast differentiation, skeletal development and bone remodeling. Wang et al., and Legner et al., showed that osteoblasts from p53 deficient mice exhibit accelerated 6 differentiation, which results in a higher rate of bone formation and bone density. This was manifested by down regulation of the key osteogenic transcription factors Ostreix or RunX2 [42, 43] . In agreement with this, two additional independent studies provided further evidence of osteogenesis acceleration in p53-null mesenchymal stem cells [44, 45] , albeit the terminal differentiation of these cells was impaired [44] . In addition to their aberrant differentiation, osteo-progenitor cells of p53-null mice also demonstrate a higher proliferation rate and may contribute to osteosarcoma formation, which is known to be abundant in p53-null mice. [43] .
Notably, in contrast to the inhibitory role of p53 in mesenchymal stem cells differentiation, p53 plays a positive regulatory role during osteogenic reprogramming of muscle committed cells [46, 47] . Thereby, p53 acts as a regulator that may either induce or inhibit osteogenic differentiation, depending on the specific cellular type and its cancerous potential.
Development of osteosarcoma may be a result of genetic and epigenetic changes that interrupt normal osteogenic differentiation of mesenchymal stem cells [48] . Interestingly, p53 was found to be frequently inactivated in human and mouse osteosarcoma cell lines [49] [50] [51] [52] .
Furthermore, patients with the Li-Fraumeni syndrome, which usually harbor a germline p53 mutation, are at high risk to develop osteosarcomas [53] . The study of Radinsky et al., shows that reintroduction of wild-type p53, but not mutant p53, into p53-null human osteogenic sarcoma cells results in terminal differentiation and apoptosis, and in inhibition of lung metastases upon the injection of these cells to mice. Thus, linking p53-deficiency to aberrant differentiation, which leads to tumor formation [41] .
p53 and myogenic differentiation
The skeletal muscle differentiation program involves expression of defined myogenic regulatory transcription factors and is coupled with a permanent withdrawal from the cellcycle [54] . Skeletal muscles of p53-KO mice develop normally [9] , and an excellent formation of myotubes was observed during the process of muscle regeneration in p53-KO mice [55] . In contrast, several in vitro studies have reported that p53 is required for myogenic differentiation. This discrepancy might be a result of the different triggers required for inducing differentiation under in vitro and in vivo conditions. Initially, it was shown that p53 mRNA levels are up-regulated during myogenic differentiation [56] . It was further demonstrated that during myogenic differentiation of immortal and primary murine myoblasts, endogenous wild-type p53 protein becomes transcriptionally active. Introduction of a dominant-negative p53 peptide into these cells resulted in inhibition of terminal differentiation into myotubes. This p53 inactivation did not alter the cell-cycle withdrawal typical of terminal differentiation, indicating that interference with endogenous p53 directly affects cell differentiation, independently of its ability to induce cell growth arrest [57, 58] . Later on, the works of Tamir and Bengal and Porrello et al., shed light on the mechanism by which p53 regulates myogenic differentiation. While Tamir and Bengal suggested that p53 is involved in the activation of muscle creatine kinase, Porrello et al., reported that p53 is responsible for up-regulation of pRb at the transcriptional level, which is essential for induction of the muscle differentiation program, together with the MyoD regulatory factor [59, 60] . Finally, Cam et al., showed that all three p53 family members (p53, p63 and p73) cooperate to promote skeletal muscle differentiation. It appears that while p53 transactivates the pRb gene; p63 and p73 induce the cyclin-dependent kinase inhibitor p57 to maintain pRb in an active, hypophosphorylated state. The activation of the pRb protein is important for permanent cell-cycle withdrawal and transactivation of musclespecific genes [18, 61] .
The inactivation of all three p53 family members by a dominant negative peptide represses myogenic differentiation and, in cooperation with other oncogenes, contributes to malignant transformation of the myoblasts [61] . Additionally, alteration of the p53 pathway has been implicated in disruption of muscle progenitor cell differentiation and promotion of rhabdomyosarcoma (RMS) formation [62] [63] [64] , which is a family of soft tissue tumors associated with the myogenic lineage [65] . The fact that p53 contributes to RMS development is substantiated by the observation that both p53 heterozygous mice, [66] , and in Li-Fraumeni patients [53] exhibit a high incidence of RMS.
Thus, myogenic differentiation provides additional evidence linking the regulatory function of p53 during in differentiation and its critical role as safeguard of proper cell maturation and tumor formation.
p53 in differentiation of hematopoietic cells
During the process of blood production, hematopoietic stem cells (HSCs) give rise to a hierarchy of differentiating progenitor cell populations that can constantly repopulate the blood system [67] . Although abnormality of hematopoiesis was not initially observed in p53-KO mice [9] , in-depth studies demonstrated that p53 do play a role in the differentiation of hematopoietic cells [68] . This was evident in the process of B-cell maturation, where it was found that reconstitution of wild-type p53 in an early pre-B cell line that lacks p53 expression (L12) resulted in the maturation of these cells, as manifested by expression of the μ immunoglobulin heavy chain and the B-cell-specific surface marker, B220. Furthermore, when these cells were injected into syngeneic mice, they induced a lower incidence of tumors and these tumors were less aggressive compared to the p53 deficient parental cell line [69] .
This may suggest that the differentiation block in the p53-deficient cells enhances their tumorigenic potential. Treatment of another pre-B cell line (70Z/3), which expresses wildtype p53, with the differentiation inducer lipopolysaccharide (LPS) or with γ irradiation resulted in increased levels of p53 mRNA in these cells. This was accompanied by the induction of κ light chain. Accordingly, it was found that p53 trans-activates the promoter of the κ light chain gene. In contrast, however, over-expression of mutant p53 in these cells interfered with their ability to differentiate [70, 71] . In addition, LPS treatment of the wildtype p53 expressing pre-B cells, 13A60, led to increased p53 mRNA levels and to secretion of IgA antibodies. These results suggested that p53 is involved in regulation of B-cell differentiation, a pathway requiring genomic rearrangements that may be accompanied by generation of faulty DNA [70] . Recently, Slatter and colleagues generated a transgenic mouse model (mDeltapro) lacking the proline-rich domain of p53. mDeltapro mice develop a lateonset B cell lymphoma comprised of incorrectly differentiated B-cells, leading the authors to suggest that by keeping B-cell populations in check, p53-dependent apoptosis prevents development of lymphomas from irregular B-cells [72] . undergo apoptosis, whereas differentiation is mediated by low levels of p53 [75] . In agreement with the abovementioned findings, granulocytic differentiation of myeloid precursor cells and primary bone marrow cells was inhibited by p53 dominant-negative peptides interfering with the endogenous wild-type p53 expressed in these cells [57, 58] . p53 over-expression induced the differentiation of the leukemic monoblastic U-937 cells, as well as facilitated their differentiation following Vitamin D3 treatment [76] . Notably, this p53-mediated differentiation induction was shown to depend on its transcriptional activity [77] .
A positive role of p53 in erythropoetic differentiation was demonstrated in K562 cells, an erythroid acute-phase chronic myeloid leukemia cell line [57, 76, 78] and in Friend erythroleukemia cells [79] . In addition, it was demonstrated that p53-dependent apoptosis is required for the final stages of normoblast differentiation, resulting in nuclear condensation and expulsion without cell death [80] . Mechanistically it appears that in the maintenance of erythropoietic homeostasis, Glucocorticoid receptor and p53 function as opposing forces; the former favoring proliferation of erythrocytes under stress conditions [81] , while the latter counteracts its proliferative effects, thereby favoring differentiation [82] .
p53 is also activated during megakaryocytic differentiation, and its role is to control polyploidization and the transition to endomitosis by impeding cell cycling and promoting apoptosis [83, 84] .
The earliest stages of blood development begin with the long-term repopulating HSCs that then differentiate into short-term repopulating HSCs and non-self renewing multipotent progenitors. These cell populations are capable of differentiating into a spectrum of mature blood cells, but differ in their self-renewal and proliferative capacity. Long-term HSCs express high levels of p53 transcripts. The relative quiescence of long-term HSCs likely protects these cells from exposure to reactive oxygen species and toxic metabolites that could lead to DNA damage. Thus, the upregulation of p53 in these cells may play an important role in maintaining their integrity [85] . Moreover, by using a variety of in vivo and in vitro assays, Liu et al., have shown that HSCs quiescence is impaired in the absence of p53, and that p53 function is essential for the enhanced stem cell quiescence observed in Mef-null mice [86] .
Thus, the dual role played by p53 in hematopoesis; inducing proper cellular maturation as well as maintaining the quiesence of the stem cell population contributes to the homeostasis of the hematopetic system, assuring the prevention of malignant transformation.
p53 and adipogenic differentiation
Adipocytes arise from mesenchymal stem cells by a sequential pathway of distinct differentiation stages. The principle regulators, which are indispensable for white fat formation, are proliferator-activared-receptor-γ (PPARγ) and CCAAT/enhancer-binding protein (C/EBP) [87] . Early studies demonstrated that p53 is downregulated during adipogenic differentiation of 3T3-L1 preadipocytes [88] and exhibits a reduction in its DNAbinding activity [89] , suggesting a negative role in regulating adipogenesis. In contrast, it was recently shown that the protein levels of p53 remain constant during adipogenic differentiation of 3T3-L1 cells. Moreover, in late stages of this differentiation, p53 is phosphorylated on two N-teminal residues, which may indicate its activation [90] . We and others have observed an increased adipogenic differentiation potential in p53-null mesenchymal stem cell populations [45, 47, 91] . In part, these results could stem from
The notion that p53 negatively regulates adipogenesis was also supported by in vivo studies. p53 is highly induced in adipocytes of the genetically obese ob/ob mice in a fed state.
This induction leads to a suppression of sterol regulatory element-binding protein-1 (SREBP-1), a key transcriptional regulator of triglyceride synthesis and the concomitant downregulation of lipogenic enzymes. This data suggest that p53 activation might constitute a negative feedback loop against excess fat accumulation in adipocytes [92] . In addition, transgenic mice over-expressing an active p53 form exhibit a reduction in body mass, adipose tissue deposition and subcutaneous adipose tissue [93] .
The negative effects exerted by p53 on adipogenesis and body fat accumulation may be linked to alterations in metabolism, which are considered one of the hallmarks of cancer [94] . Accordingly, p53 was reported to regulate both oxidative phosphorylation and glycolysis, an important feature for its ability to suppress tumorigenesis [95] . p53 was shown to regulate energy metabolism by tilting the balance between the glycolitic and respiratory pathways. This effect is mediated, at least partially, by p53-dependent trans-activation of Cytochrome-C-Oxidase-2 (CCO2), which is essential for mitochondrial respiration [96] , and TP53-Induced-Glycolysis and Apoptosis Regulator (TIGAR) that inhibits glycolysis [97] .
Thus, in p53-deficient cells there is a shift from oxidative phosphorilation towards glycolysis [96] . This shift may increase the availability of Acetyl-CoA molecules as substrates for fatty acid synthesis and may contribute to the increased accumulation of fat.
Recently, p53 was shown to play a crucial role in the regulation of insulin resistance in adipose tissue [98] . The adipose tissue of genetically obese mice suffering from insulin resistance exhibited features of premature aging and inflammation. These senescence-like changes were manifested by increased expression of senescence associated β-galactosidase, elevated p53 levels and high expression of pro-inflammatory cytokines. Inhibition of p53 in the adipose tissue decreased the inflammation and improved insulin sensitivity [98, 99] .
The adipose tissue serves not only as an organ for an energy storage in the form of triglycerides, but also as an endocrine and a metabolic organ. In response to endocrine and metabolic signals from other organs, the adipose tissue may secrete free fatty acids, hormones and cytokines which can affect the function of other tissues [100] . Impaired adipogenic differentiation may eventually result in obesity. Obesity in turn, induces a variety of pathological conditions such as type 2 diabetes, fatty liver and cardiovascular pathology, which are in large part a result of insulin resistance [87] . In addition, epidemiological studies indicate that obesity is associated with increased risk of cancers such as colorectal, breast, endometrial, kidney, liver and others. However, the biological mechanisms that link obesity to cancer and the role of p53 in this pathway are still poorly understood [101] .
Overall, the abovementioned studies demonstrate an important role for p53 in maintaining proper differentiation and function of the adipose tissue, which may provide a link between obesity, aging, abnormal metabolism and cancer. Indeed, a recent work revealed that p53 is a regulator of polarity in the divisions of mammary stem cells and in its absence, cells acquired self renewal properties as those typical for cancer stem cells, rather than normal stem cells [110] . Other reports show that p53 negatively regulates self renewal and drives hematopoietic stem cells toward quiescence, through two p53 target genes, Gfi-1 and Necdin [86, 111, 112] . Similar properties were also shown in adult As p53 was already found to be involved in the regulation of various stem cell properties, its involvement in the regulation of cellular reprogramming is not surprising. In mouse embryonic stem cells (ESCs), p53 was shown to bind the promoter of Nanog, a key gene required for ESCs self renewal, and to suppress its expression following DNA damage [116] . The reduced expression of Nanog led to ESCs differentiation, enabling their cell-cycle arrest, and a subsequent repair of the damaged DNA, or alternatively, in case of a persistent damage, to programmed cell death. Thereby, p53 likely serves to maintain the genomic integrity of the ESCs. Similarly, activation of p53 by Nutlin, an inhibitor of p53-Mdm2 interaction [117] , in human ESCs, prevents S-phase entry and subsequently leads to cellcycle arrest [118] . Finally, germ cells were demonstrated to be spontaneously reprogrammed in the absence of p53 [119] .
In addition to the roles of p53 in regulating the DNA damage response, proliferation and self renewal in stem and progenitor cells, it was also shown to be implicated in the core regulatory circuit of the factors used for the reprogramming process. As mentioned above, p53 represses Nanog in ESCs following DNA damage [116] . It was also shown that in certain contexts, Klf4, one of the factors required for reprogramming, can directly repress p53 transcription in mouse embryonic fibroblasts (MEFs). This study showed that when Klf4 is over-expressed alone, the expression of the cell-cycle regulator, p21, was increased, leading to cell-cycle arrest. However, in conjunction with the Ras V12 oncogene, p53 was repressed, which eventually resulted in cell transformation [120] . A reciprocal trans-activation of Klf4 by p53 was also demonstrated [121, 122] . The regulatory circuit between Klf4, p53 and Nanog raised the possibility that p53-deficiency may substitute for the role played by Klf4 in the reprogramming process. This hypothesis was tested by several groups; While Zhao et al.,
failed to reprogram p53-deficient human cells in the absence of KLF4, Kawamura et al.,
showed that using p53-deficient mouse embryonic fibroblasts, iPS cells can be produced with only Oct4 and Sox2, although at a very low yield. This demonstrates that p53 reduction does not completely substitute for the role of Klf4 in the process of iPS cells generation. [106].
In contrast to the suggested role of p53 in restraining de-differentiation of somatic cells into pluripotent stem cells, Hanna et al., claimed that p53 does not directly play a role in this process, and its effect is only due to its function as a regulator of the proliferation rate of the cells. This was supported by inhibition of the p53-p21 pathway or, alternatively, over expression of Lin28, which promoted proliferation and enhanced the efficiency of iPS formation in direct proportion to the increase in proliferation rate [124] .
Overall, it seems that p53 inhibition enhances the reprogramming process, increasing both the yield of the generated iPS cells and the rate of their formation. However, in spite of the scientific worldwide race towards achieving better and more efficient techniques to reprogram cells, the use of p53 elimination in this process should be considered with great caution since reduction in the levels of this tumor suppressor protein may be detrimental for the integrity of the reprogrammed cells. One can speculate that in the absence of an appropriate defense mechanism, the reprogrammed cells will be transformed and give rise to cancer initiating cells [125, 126] . Indeed, we have found that reprogramming of cells in which the p53 pathway is abrogated give rise to cells with pluripotential capacity in vitro, but upon injection to nude mice these cells induced the formation of malignant tumors ( [127] , submitted). This concern is supported by the demonstration that mouse fibroblasts lacking the pRb tumor suppressor function undergo aberrant reprogramming, yielding transformed cells capable to initiate tumor formation [128] . Also, several of the recently published studies show preliminary evidence for the risks of eliminating p53 in the reprogramming process. For instance, Marion et al., reported that iPS cells deficient of p53 exhibit foci of DNA damage and chromosomal aberrations, as well as loss of their typical round morphology after expansion [106] . Moreover, mice generated from p53-null iPS cells died of tumors originating from these cells [103] . Trying to circumvent the tumorigenic potential of p53-null iPS cells, it was suggested that a transient suppression of p53 during reprogramming may be useful for future iPS cell production for medical use. However, if p53 is required for maintaining the genomic integrity of the cells throughout the reprogramming process, this may still give rise to abnormal iPS cells.
The connection between reprogramming and cancer is further supported by the observation that while c-Myc is a well-known oncogene; Klf4 appears to display both growth inhibitory and growth promoting abilities, depending on the cell type [120] . Oct4 was shown to act as a dose-dependent oncogenic fate determinant, and ectopic expression of Oct4 was reported to promote dysplastic growth in epithelial tissues [129, 130] . Nanog expression in NIH3T3 cells drives the cells toward transformation [131] , and leads to a differentiation block of myoblasts [132] . Lin28 was also shown to promote transformation and to play a role in germ cell malignancy [133, 134] . These data are not surprising considering the fact that part of their role as stemness factors is to maintain cells in a self renewal, proliferative state. This concept is further highlighted by studies demonstrating the tight link between cancer and
ESCs. It was shown that aggressive poorly differentiated human tumors have an embryonic stem cell like gene expression pattern [135] , and that activation of an ESC-like transcriptional program can induce epithelial tumor initiating cells [136] .
As cancer cells and ESCs share common features in general, and more specifically, In sum, these recent discoveries suggest that in agreement with the well-accepted notion that p53 is the genome guardian at large, it plays a pivotal role in maintaining the genomic stability of embryonic stem cells and reprogrammed cells, restraining dedifferentiation, transformation and further proliferation of abnormal cells. Based on histological similarities between tumors and embryonic tissues, it was suggested that tumors in adults develop from embryonal rudiments that remained in matured organs.
This theory was later re-examined by Conheim who suggested that tumors develop from residual embryonic remnants that were 'lost' during developmental organogenesis [140] . This theory was further revisited in 2004 when it was postulated that tissue stem cells are the modern-day equivalent of "embryonal rest" and that most tumors arise from the maturational arrest of a cellular lineage derived from a tissue stem cell [141] . Recent evidence demonstrating the existence of cells expressing Oct4 and Nanog in adult tissues [142] , and the fact that human tumors were shown to have an embryonic stem cell like gene expression The major function of p53 as a tumor-suppressor is to promote cell-cycle arrest and apoptosis. As described above, via these functions, p53 is involved in various differentiation programs. In addition, its restraining activity along reprogramming was shown to involve its functions in inducing DNA damage repair, apoptosis or cell cycle arrest. However, a more direct role of p53 in differentiation, by regulating the expression of key differentiation proteins was shown for several programs (Table I) . Few examples include the regulation of Runx2 or Osterix in osteogenesis [146] , PPARγ in adipogenesis, myocardin in smooth-muscle differentiation [47] , and Wnt7b and Tfcp2l4/Grhl3 in neural differentiation [36] . Thus, although differentiation coincides with cell-cycle arrest and apoptosis, in addition to these well-known functions of p53, it also plays a direct role in the regulation of specific factors responsible for proper cellular maturation. It will be interesting to determine whether p53 also plays such a direct role during reprogramming, by regulating specific genes required for this complex process.
In sum, the regulation of proper differentiation and de-differentiation processes by Wild-type p53 is a homeostatic gene promoting proper differentiation and development in order to prevent tumorigenesis. This is mediated by its well established roles as an inducer of the cell-cycle arrest and apoptosis, to prevent abnormal maturation of stem and progenitor cells. p53 also regulates dedifferentiation by restraining somatic cells reprogramming, thus preventing the formation of abnormal stem-cells, which may lead to tumor development. In contrast to the tumor suppressive activity of the wild-type protein, mutant p53 abrogates p53-dependent activities in controlling differentiation and de-differentiation processes, blocking differentiation and promoting tumorigenesis. 
